grafting after high-dose chemotherapy. One of the potential advantages is the possibility t o reduce the volume of blood processed from the patient, thus allowing reduction of the overall tumor cell number in the final autograft. However, ex vivo expansion will only be advantageous if contaminating tumor cells are not expanded concomitantly. This question has not previously been addressed. Therefore, we analyzed unseparated PBPC preparations, CD34+-selected cell fractions, and ex vivo-expanded cell preparations from stage IV (n = 16) and high-risk stage 11/111 (n = 8) breast cancer patients for the presence of human epithelial antigen-(HEA) or cytokeratin (CK)-positive tumor cells. We found that three of 16 (18.8%) of the unseparated PBPC products from stage IV patients were HEA-and/or CK-positive, whereas none of the stage 11/111 patients were found t o be positive after t w o cycles of induction chemotherapy with etoposide (VP161, ifosfamide, cisplatin, and epirubicin (VIP-E). After CD34+ cell selection (Ceprate SC; CellPro, Bothell, WA) and stem-cell factor (SCF), interleukin (ILI-I, IL-3, IL-6, and erythropoietin (EP0)-mediated ex vivo expansion of the CD34' cells for 14 t o 21 days, no tumor cells could be detected in these primary breast cancer patients at a sensitivity of 1 tumor cell per 4 x I O 5 nucleated cells. Thus, t o answer the question of whether tumor cells are expanded concomitantly on ex vivo expan-ERIPHERAL BLOOD progenitor cells (PBPCs) have P replaced bone marrow cells as the major source of hematopoietic support after high-dose chemotherapy. They provide several advantages over bone marrow cells, including a considerably faster recovery of hematopoiesis.'.' Although tumor cell contamination of PBPCs does 0ccur,3-~ and tumor cells can be recruited into the circulation upon mobilization of PBPCS,~ its clinical relevance is still a matter of debate. Only gene-marking studies"' ' and retrospective clinical trials1'.13 support the observation that contaminating tumor cells in the autograft might be predictors for relapse and overall survival posttransplant. Therefore, several attempts have been made to reduce the risk of tumor cell contamination, including in vivo purging with at least two cycles of cytoreductive chemotherapy before progenitor-cell har~est,*.'~-'~ as well as ex vivo purging upon positive-selection of CD34+ cell^.^^" Additional tumor reduction might be possible by reducing the volume of blood processed from the patient, followed by ex vivo expansion of CD34' cells in cytokine-supported liquid culture^.^^-^^ We recently demonstrated that a combination of stem-cell factor (SCF), interleukin-18 (IL-I), IL-3, IL-6, and erythropoietin (EPO) effectively mediates the expansion of committed progenitor cells and maintains the number of more primitive stem cells.20,22 Moreover, we have shown in a clinical phase I trial that autologous progenitor cells generated ex vivo from a small number of the patient's CD34+ cells rapidly reconstitute hematopoiesis after high-dose chem~therapy.~"'~ However, ex vivo expansion of CD34+ cells is only advantageous if potentially contaminating tumor cells are not expanded concomitantly, a question that has never been addressed before. Therefore, we analyzed PBPC preparations sion of normal CD34+ cells, we cocultured defined numbers of primary renal carcinoma cells (RS-85). xenograft-derived breast cancer cells, and small-cell lung cancer cells with CD34+ cells selected from normal donors or cancer patients, either in serum or serum-free culture media. We found that none of the three epithelial tumor cell types increased significantly in number during a 14-day coculture period when compared with normal CD34+ cells alone or tumor cells alone, which increased 110-* 77-fold and 45-? 26-fold, respectively. However, during coculture, the tumor cells did not undergo cell death and were able t o regrow when maintained in serum for longer time periods. We conclude that cytokine-supported expansion cultures of positively selected CD34+ PBPCs from primary high-risk stage 11/111 or stage IV breast cancer patients do not contain detectable tumor cells, which suggests that there is no increased risk of concomitantly expanding tumor cells. Moreover, cocultures of exogenously mixed tumor cell lines with normal CD34' cells showed a relative disadvantage of tumor cell growth compared with the growth of hematopoietic cells, again without an apparent risk of concomitantly expanding tumor cells. However, considering the pronounced heterogeneity of tumor cell kinetics, ex vivo-expanded PBPC from cancer patients should be monitored for minimal residual disease. 0 1996 by The American Society of Hematology.
from stage IVIII and stage IV breast cancer patients before and after ex vivo expansion of positively selected CD34' cells for the presence of epithelial tumor cells. CD34' cell selection is a prerequisite for successful ex vivo expansion of PBPCs, resulting in a 1-to greater than 4-log reduction of contaminating tumor cells, as demonstrated in breast ~a n c e r ,~ non-Hodgkin' s lymph~ma,'~ or multiple myeloma.26 Using currently available immunocytologic or polymerase chain reaction (PCR)-based assays for the quantitation of malignant cells, between 62% and 100% of the positively selected CD34+ cell fractions are purged below the level of detection,7.2S.26 and remaining tumor cells can only be detected at extremely low numbers, ie, less than 1 cell per 1 x lo6 2708 VOGEL ET AL positively selected CD34' cells.'.'6 The limits of sensitivity with these methods suggest that a maximum of 350 to 1,000 tumor cells could have remained in the autograft after CD34' cell selection in breast cancer patients7
These data provided the basis for the present study, in which we investigated whether endogenous tumor cells from patients with primary breast cancer are expanded concomitantly to normal CD34+ hematopoietic cells when cultured ex vivo in SCF, IL-1, IL-3, IL-6, and EPO-containing media. Moreover, we performed coculture experiments of allogeneic CD34' cells with exogenously mixed primary renal carcinoma (RS-85) or xenograft-derived breast and smallcell lung cancer cells to quantitatively measure the tumor cell numbers during different time points of ex vivo culture. We found that neither primary tumor cells from breast cancer patients nor xenograft-derived tumor cells were expanded under serum-free conditions during cytokine-supported liquid cultures of CD34' PBPCs.
MATERIALS AND METHODS
Patients, PBPC harvest, and positive selection of peripheral blood CD34' progenitor cells. Patients with high-risk stage IInII (n = 8) and stage IV (n = 16) breast cancer undergoing high-dose chemotherapy were included. PBPCs were collected after the second cycle of etoposide (VP16). ifosfamide, cisplatin, and epirubicin-based chemotherapy (VIP-E),'* and granulocyte colony-stimulating factor (G-CSF; Neupogen; 5 ,ug/kg; AMGEN, Munich, Germany). In addition, PBPCs from four allogeneic healthy donors and from two patients with testicular cancer were collected. These cells were used in coculture experiments, as described later. Written informed consent was given by all patients and normal allogeneic donors.
Clinical scale positive selection of CD34' PBPCs was performed with the Ceprate SC stem-cell concentrator (Cellpro, Bothell, WA)." The median percentage of the CD34' cell fractions after immunoselection was 68.2% (range, 56.3% to 78.7%).
Ex vivo expansion of positively selected CD34' PBPCs from primary breast cancer patients in cytokine-supported liquid cultures. Positively selected CD34' cells from primary stage IV (n = 16) and stage IMII high-risk (n = 8) breast cancer patients were cultured in the presence of SCF, IL-1, IL-3, IL-6, and EPO, and analyzed at different time points (days 7, 14, and 21) for the presence of contaminating tumor cells (see later). The CD34+ cells were cultured at 1.5 X I 04/mL in RPMI-1640 medium and supplemented with recombinant human SCF (10 ng/mL; Genzyme, Russelsheim, Germany), L I P (3 ng/mL; Genzyme), IL-3 (100 ng/mL), IL-6 (100 ng/mL) (both kindly provided by L. Farber, Sandoz, Numberg, Germany), and EPO ( I U/mL; Cilag, Sulzbacms, Germany).2"~2' The cultures were either performed in 10% fetal calf serum (FCS) or in serum-free medium (Xvivo; Serva, Heidelberg, Germany).
Human xenografr-derived tumor cells and primary renal carcinoma cells. The human small-cell lung cancer LXFS 650 xenograft and the human breast cancer MCF-7 xenograft grown previously in nude mice were processed according to standard procedures (kindly provided by Drs M. Dengler and H.H. Fiebig, University of Freiburg, Germany). In addition, primary human renal carcinoma cells were obtained from a patient undergoing surgery for metastatic renal cell carcinoma (RS-85 cells; kindly provided by Dr M. Lahn, University of Freiburg, Germany). The tumor cells were grown in 75-cmZ tissue culture flasks in supplemented RPMI-I640 medium (Biochrom, Berlin, Germany) with 10% FCS (Pansystems, Aidenbach, Germany). They were passaged once a week and supplemented with fresh medium. RS-85 cells and MCF-7 cells were trypsinized for 10 minutes at 37°C (GIBCO, Paisley, Scotland), whereas LXFS small-cell lung cancer cells were grown in suspension.
Coculture of positively selected CD34' PBPCs with or without exogenously mixed tumor cells. Control cultures of CD34+ cells alone or the three different tumor cell types alone were performed to demonstrate growth of these cells in cytokme-supported liquid cultures. All experiments were performed in duplicate in six-well flat-bottom tissue culture plates (Falcon, Heidelberg, Germany). Each culture consisted of a volume of 2 mL. For coculture experiments, xenograft-derived tumor cells (LXFS or MCF-7), as well as primary renal carcinoma cells (RS-85), were plated into the CD34' cells at 10%. 1.5%, and 0.2% of all cells, ie, an absolute number of 1,500 tumor cells/mL, 225 tumor cellslml, and 30 tumor cellslml, respectively. The cells were cultured for 14 days, in some experiments with LXFS cells up to 21 days at 37°C in 5% COZ without additional feeding. At different time points during ex vivo culture, total cells from each well were harvested, trypsinized, washed twice with phosphate-buffered saline (PBS), counted, and resuspended in PBS for subsequent immunocytologic tumor cell analyses. The viability of the cells was greater than 95% by trypan blue dye exclusion.
Transwell experiments were performed in six-well plates with 25-mm cell culture inserts (Cyclopore membrane, 0.45-pm pore size: Falcon, Heidelberg, Germany) to address the issue of humoral versus cell-to-cell interactions during coculture of CD34+ PBPCs and tumor cells.
The tumor cell assay was performed as described previously.' Briefly, ( I ) tumor cells alone, (2) unseparated PBPCs, (3) positively selected CD34' cells, and (4) ex vivo-expanded CD34+ PBPCs from the primary breast cancer patients were attached to poly-L-lysinecoated adhesion slides (Marienfeld, Bad Mergentheim, Germany). Moreover, exogenously mixed suspensions of CD34' cells and the three different tumor cell types were evaluated for tumor cell numbers at different time points after ex vivo culture. After washing the cell preparations in PBS, the cell density was adjusted to 2.5 to 5 x IOh/mL. At least 100 p L of the cell suspension was attached on each spot. A total of six spots was analyzed from each preparation (ie, 1.5 to 3 x IOh total nucleated cells). Antibody staining was performed with anticytokeratin and antihuman epithelial cell antigen (HEA 125) antibodies: clone AEl/AE3 (immunoglobulin GI [IgCl]; Boehringer Mannheim, Mannheim, Germany), clone KLI (1gG I ; Dianova, Hamburg, Germany), and clone HEA 125 (IgGI; Progen, Heidelberg, Germany).* An APAAP assay (DAKO, Hamburg, Germany) was performed and developed twice to increase chromogen intensity. An irrelevant IgGl isotype served as a negative control, whereas the tumor cells were used as positive controls. The number of total cells present on each spot was enumerated, as described.x A computer program (PAW, Version 2.03) was used for calculation. and the error in the calculated cell number was less than 6%. The sensitivity of 1 tumor cell per 4 X 10' nucleated cells was maintained even after CD34' selection and ex vivo expansion, as demonstrated by coculture experiments (data not shown).
The statistical significance of the data obtained was analyzed with the nonparametric Mann-Whitney-test (Instat; GraphPad Software, San Diego, CA). A two-tailed P value less than .05 was considered significant lmmunocytologic assay for the detection of tumor cells. preparations (18.8%) from stage IV breast cancer patients were found to be positive at a frequency of 0.6 to 1.9 per 1 X lo6 mononuclear cells (Table 1) . This represents a maximal tumor cell number of approximately 18 X IO3 to 46 X lo3 tumor cells per apheresis. None of the unmanipulated PBPC preparations from stage M I 1 high-risk breast cancer patients were found to be positive (Table 1 ). After CD34+ cell selection, none of the cell populations contained cytokeratin (CK)-or HEA 125-positive tumor cells (Table 1) . MCF-7, or primary RS-85 renal carcinoma cells in serumcontaining expansion medium alone showed a 32-to 58-fold increase in numbers over a 14-day culture period (Table 2) . This was independent of the cell numbers seeded per culture (10% = 3,000 cells/well; 1.5% = 450 cells/well; or 0.2% = 60 cells/well; data not shown). The rate of expansion of the CD34+ cells was 110-2 77-fold at day 14 ( Table 2) .
Statistics.

RESULTS
Detection of residual tumor cells in unmnipulated PBPCs
Coculture of CD34' PBPCs from normal donors or cancer patients with the different tumor cell lines (n = 96 experiments) in 10% FCS indicated a proliferative advantage of the hematopoietic progenitor cells when compared with the tumor cells (Table 2 and Fig 1) . The total number of hematopoietic cells increased 65-? 23-fold until day 14, whereas the absolute number of LXFS tumor cells, as analyzed by immunocytology in each culture, significantly decreased until day 7 (P = .008), and subsequently increased again until day 14, to reach almost identical numbers as initially seeded at day 0 (Fig 1 and Table 2 ). The growth delay of the tumor cells as compared with the hematopoietic cells was highly significant at day 14 (P = .0025). Thus, whereas tumor cells cultured without hematopoietic cells were expanded 30-to %-fold (Table 2) , there was no expansion of tumor cells upon cocultivation with CD34' cells until day 14, independent of the tumor cell type and the concentrations seeded (Fig 1) . However, prolonged ex vivo culture until day 21 resulted in a significant increase in the absolute number of tumor cells, whereas the hematopoietic cells reached a plateau. The increase of tumor cells from day 14 to day 21 of culture was 4.4-? 3.3-fold for LXFS cells, 4.5-t 2.8-fold for MCF-7 cells, and 13-t 6.5-fold for the RS-85 cells, respectively.
To address the issue of direct cellular versus humoral interactions resulting in the decreased proliferation of tumor cells when cocultured with CD34' cells, we performed additional transwell experiments. In the transwells, LXFS, MCF-7, and RS-85 tumor cells were growing 22-t %fold, 27-? 1 I-fold, and 47-? %-fold, respectively, when the CD34' cells were cultured either in the culture inserts or in the bottom of the transwell plates. These data suggest that direct cellular interactions between ex vivo-expanded hematopoietic cells and the tumor cells rather than soluble factors might be of importance for the reduced growth of tumor cells in the coculture experiments. Moreover, the experiments demonstrate that the relative growth disadvantage of the malignant cells is not a direct function of normal accessory cells.
To replace FCS for a potential clinical application, we additionally performed experiments in cytokine-supported serum-free culture media. We observed that the growth pattern of CD34+ PBPCs alone, when cultured either in 10% FCS or in serum-free medium, was not significantly different between the two types of culture (110-t 77-fold u 89-? 56-fold; P = .11) ( Tables 2 and 3 ). In contrast, tumor cells did not grow in serum-free media, with a growth rate of 0.7-to 1.8-fold for the three different tumor cell types (Table 3) . However, when these cells were subsequently challenged with serum-containing medium, they were able to rapidly regrow (data not shown). When RS-85 tumor cells were cocultured with CD34' PBPCs in serum-free medium, there was a significant reduction in the number of RS-85 cells until day 14 as compared with FCS-containing medium ( P = .0022) (Fig 2) . Even on continued ex vivo culture until day 21 in serum-free medium, these tumor cells did not grow (0.35 ? 0.2 X IO2 tumor cells at day 21). In the clinical samples, we harvested PBPCs from patients with high-risk stage IUIII or stage IV breast cancer undergoing high-dose chemotherapy after two cycles of VIP-E induction chemotherapy." This chemotherapy regimen is active in a variety of malignancies, resulting in effective in vivo p~r g i n g .~. '~ After PBPC collection, CD34+ PBPCs were purified by the means of an immunoaffinity column, which was shown to further reduce the number of contaminating tumor cells by 2 to 4 10g.7.1*,25326 Ex vivo expansion of PBPCs has to be preceded by CD34+ cell selection, otherwise there is no consistent rate of expansion. We found that neither positively selected CD34' cells from stage IV or high-risk stage IMII breast cancer patients nor ex vivo-expanded cell preparations from these patients contained any CK-andor HEA 125-positive cells at a detection limit of 1 per 4 X lo5 nucleated cells. The finding that tumor cells were not detected in the CD34+ cell fraction was not surprising, considering an approximately 4C)o-fold depletion of non-CD34' cells, including tumor cells.7sL8 This indicates that residual tumor cells after CD34+ cell selection can only be detected with extremely sensitive assays. Ross et all6 reported that one of 11 breast cancer specimens in their study had an For personal use only. on . by guest www.bloodjournal.org From 85 renal carcinoma cells, as well as human xenograft-derived (LXFS and MCF-7) tumor cells. Moreover, we chose this coculture model due to the fact that primary breast cancer cells from bone marrow specimens or primary tumor tissue are difficult to grow in vitro. We and others found that only 20% to 30% of all primary epithelial tumor cells can be grown in vitro under appropriate culture conditions (Dr K.
Pantel, Munich, Germany, personal communication, June 1995). Our coculture results performed here indicate that both primary and xenograft-derived tumor cells are not expanded during a 14-day coculture with CD34' cells in serum-free medium, whereas the number of hematopoietic progenitor cells increases approximately 100-fold (Table 3 and Fig 3) . These data suggest that cytokine-supported ex vivo For personal use only. on . by guest www.bloodjournal.org From expansion of CD34' PBPCs contaminated with epithelial tumor cells can confer a proliferative advantage of hematopoietic cells without an apparent risk of concomitantly expanding residual tumor cells. Interestingly, none of the manipulations of the culture conditions studied resulted in a complete loss of tumor cells (Fig 3) . These cells were rather able to regrow when maintained in serum-containing media for longer time periods. Additional evidence for tumor cell survival ex vivo was given by the observation that tumor cells can be detected in long-term marrow cultures of histologically normal bone marrow specimens in both solid tumor patients and lymphoma patientsz7 Whether such cells give rise to tumor recurrence after reinfusion into patients is not known yet. Only in vivo assays with the transplantation of such ex vivo-manipulated PBPC preparations into transgenic SCID mice that carry human cytokine transgenesz8 might give further insight.
In conclusion, the experiments performed here indicate that ex vivo expansion of PBPCs from patients with nonhematologic malignancies might permit the transplantation of an autograft with an overall reduced tumor cell load when compared with the use of unmanipulated PBPCs. However, whether this translates into a better prognosis remains to be determined. Nevertheless, we would currently recommend an optimized approach for PBPC transplantation with respect to a minimal number of tumor cell contamination: (1) an in vivo purging with at least two cycles of chemotherapy before progenitor-cell harvest,* ( 2 ) the collection of a small blood sample at the time of maximal levels of CD34+ cells, followed by ( 3 ) the positive selection of CD34' cells, and finally, ex vivo expansion under serum-free conditions for 12 to 14 days. However, considering the pronounced heterogeneity of tumor cell kinetics, ex vivo-expanded PBPCs should be carefully monitored for the presence of tumor cells before transplantation.
